0001213900-23-078797.txt : 20230922 0001213900-23-078797.hdr.sgml : 20230922 20230922163031 ACCESSION NUMBER: 0001213900-23-078797 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230921 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dominari Holdings Inc. CENTRAL INDEX KEY: 0000012239 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 520849320 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-05576 FILM NUMBER: 231272108 BUSINESS ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 347-321-7646 MAIL ADDRESS: STREET 1: ONE ROCKEFELLER PLAZA, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER COMPANY: FORMER CONFORMED NAME: AIkido Pharma Inc. DATE OF NAME CHANGE: 20210111 FORMER COMPANY: FORMER CONFORMED NAME: Aikido Pharma Inc. DATE OF NAME CHANGE: 20200317 FORMER COMPANY: FORMER CONFORMED NAME: SPHERIX INC DATE OF NAME CHANGE: 20010815 8-K 1 ea185678-8k_dominari.htm CURRENT REPORT
0000012239 false 0000012239 2023-09-21 2023-09-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 22, 2023 (September 21, 2023)

 

Dominari Holdings Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   000-05576   52-0849320

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

725 5th Avenue, 23rd Floor

New York, NY 10022

(703) 992-9325

(Address, including Zip Code and Telephone Number, including

Area Code, of Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   DOMH   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

  

Item 5.02 Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 21, 2023, Mr. Robert J. Vander Zanden, Chairman of the board of directors (the “Board”) of Dominari Holdings Inc. (the “Company”), notified the Board that he was resigning as a director of the Company, and as Chairman of the Board, effective immediately. As a result of such resignation, Mr. Vander Zanden’s service as a member of the Company’s audit committee and compensation committee were also terminated, effective immediately. Mr. Vander Zanden’s resignation was not the result of any disagreement with management or the Company on any matter relating to the Company’s operations, policies or practices.

 

Following Mr. Vander Zanden’s resignation from the Board, the Board unanimously appointed Mr. Anthony Hayes, the Company’s Chief Executive Officer, as Chairman, effective September 21, 2023.

 

The Company plans to replace Mr. Vander Zanden on the audit committee and the compensation committee as soon as practically possible with director(s) each deemed to be “independent,” as defined in Nasdaq Listing Rule 5605(a)(2). The director(s) will also satisfy the independence criteria set forth in Rule 10A-3 of the Securities Exchange Act of 1934, as amended.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On September 21, 2023, the Company held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders (i) elected Messrs. Gregory Blattner, Paul LeMire, and Kyle Wool to serve as Class III directors of the Company; (ii) ratified the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023; (iii) approved, on a non-binding, advisory basis, the Company’s executive compensation; and (iv) approved, by a non-binding advisory vote, that future non-binding advisory votes on compensation paid by the Company to its named executive officers be held every three years.

 

Stockholders of record at the close of business on July 27, 2023 (the “Record Date”) were entitled to one vote for each share of common stock, 0.007285 votes per share of Series D convertible preferred stock (“Series D Preferred Stock”) and 0.007285 votes per share of Series D-1 convertible preferred stock (“Series D-1 Preferred Stock”). 

 

On the Record Date, there were 5,345,312 shares of common stock outstanding, 3,825 shares of Series D Preferred Stock outstanding and 834 shares of Series D-1 Preferred Stock outstanding. The amount of issued and outstanding shares of common and preferred stock present at the Annual Meeting was sufficient to constitute a quorum.

 

Set forth below are the final voting results for each of the proposals:

 

Proposal No. 1 – Election of directors

 

Messrs. Gregory Blattner, Paul LeMire, and Kyle Wool were elected to serve as Class III directors of the Company for a term expiring at the 2026 annual meeting of stockholders or until their successors are elected and qualified. The voting results were as follows:

 

Director  Votes For  Votes Withheld  Broker
Non-Votes
 
Gregory James Blattner  1,592,087  333,327  - 
Paul LeMire  1,622,014  303,400  - 
Kyle Wool  1,601,962  323,452  - 
           
Total:  4,816,063  960,179  994,504 

 

1

 

 

Proposal No. 2 – Ratification of the appointment of independent registered public accounting firm

 

The appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The voting results were as follows: 

 

Votes For  Votes Against  Abstentions
2,817,343  55,689  46,866

 

Proposal No. 3 – Approval, by non-binding advisory vote, of the Company’s executive compensation

 

The Company’s executive compensation, by non-binding advisory vote, was approved. The voting results were as follows: 

 

Votes For  Votes Against  Abstentions  Broker Non-Votes
1,501,174  411,902   12,338  994,504

 

Proposal No. 4 – Approval, by non-binding advisory vote, for the frequency of future non-binding advisory votes on executive compensation

 

The Company’s stockholders recommended, on a non-binding advisory basis, three (3) years as the frequency with which the Company should hold future non-binding advisory votes on the compensation of the Company’s named executive officers (the “Say-on-Pay Vote”). The voting results were as follows:

 

One Year  Two Years  Three Years  Abstentions
597,276  5,813   1,293,210  29,115

 

 Consistent with a majority of the votes cast with respect to this proposal and with the recommendation of the Board, the Company will hold Say-on-Pay Votes every three years, unless the Board determines, in its discretion, to hold votes on a different frequency. The next non-binding advisory vote regarding the frequency of the Say-on-Pay Vote is required to occur no later than the annual meeting occurring six years after the Annual Meeting, which will be the Company’s 2029 annual meeting of stockholders.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 22, 2023 DOMINARI HOLDINGS INC.
     
  By:

/s/ Anthony Hayes

  Name:  Anthony Hayes
  Title: Chief Executive Officer

 

3

 

 

EX-101.SCH 2 domh-20230921.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 domh-20230921_def.xml XBRL DEFINITION FILE EX-101.LAB 4 domh-20230921_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 domh-20230921_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Sep. 21, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 21, 2023
Entity File Number 000-05576
Entity Registrant Name Dominari Holdings Inc.
Entity Central Index Key 0000012239
Entity Tax Identification Number 52-0849320
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 725 5th Avenue
Entity Address, Address Line Two 23rd Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code 703
Local Phone Number 992-9325
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol DOMH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 ea185678-8k_dominari_htm.xml IDEA: XBRL DOCUMENT 0000012239 2023-09-21 2023-09-21 iso4217:USD shares iso4217:USD shares 0000012239 false 8-K 2023-09-21 Dominari Holdings Inc. DE 000-05576 52-0849320 725 5th Avenue 23rd Floor New York NY 10022 703 992-9325 false false false false Common Stock, $0.0001 par value DOMH NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,^#-E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #/@S973Q\C&.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)TUAP=#M1?&D(+B@> O)[&ZP24,RTN[;F\;=+J(/X#$S?[[Y M!J;30>HQXG,< T:RF&YF-_@D==BR(U&0 $D?T:E4YX3/S?T8G:+\C <(2G^H M X+@? ,.21E%"A9@%58BZSNCI8ZH:(QGO-$K/GS&H<",!AS0H:<$3=T ZY>) MX30/'5P!"XPPNO1=0+,22_5/;.D .R?G9-?4-$WUU)9L%%6_';2HB=X++E4FS>%]97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MSX,V5[CDVCM9! $A$ !@ !X;"]W;W)K=28(M((04F"&0-)F[)%R@O;EV^D'8 C2Q)9\D0_+O MNS+$YE*S)A^";;RO'^^N7ZWI;91^,2O.+7E-8FGZWLK:]*K1,.&*)\RX MO_VN?IO?/-S,G!D^4O%7$=E5W[OT2,07+(OML]K<\=T-Y8"ABDW^GVRVY[9: M'@DS8U6R"P:"1,CM)WO=)6(OH$D/!-!= ,VYMQ?**;1 ">DJ\K4:OA60)P=C-2:ZU[#@I0[T AW8=?;,'H@;,K3;>X)>? M@@O_=X2O6? U,?7!6(49]*(EL[>45\'AX9=GGQ"(5@'10E6&0!#E%+SC$\SWPI7&=#SAY94IDH7&>LX-EG6I [ M%4="+LW)O0S/$<#+ O#R&, 1E%.SF-S+B+^23_RM"A%7\MU?0&FSBV!U"ZSN M,5@S]DKN(V 3"Q&RW,8/5Q57;-,S_[+5;5(?P0O\TC;]8P"A"DJG2N=LIV1J MX3$@2I.1RB"AD%<555:[1GU\@T'N>7MP#.0PBL 1S>G[!OD,YY$G64V&2W9H M^Z1M5V2XYC+#S"0HK3] G1NGG&U4)24N29LZ.KF-E=(886G^ 6[?'PE';@^J M/%,;64F'RSW"K/(-9A6,K5P3 MS4/[(5+3C1:BUD6%UD7//Q&X96+A,![NX? MT2;*6/"8OT5Z^+G %0/?IQ1C*]>) #?YO(1#F&,/H^ "'1];KX)R@0AP9_^L M0LC)9*4DMF+5B'2[] RLK8T1E2M"@!OY5RVLY1(2DR29W/FNJ:3"A>KFC:!< M#0+X5<\T<^,6F;XE M'.XRD]'F*>_)[HLC-:[AB9? W M"==+EZ4_0 %F RA,RF1U27'!@VW6V'O#=;\6/#!W14-BO@ A_[P#NGK[ K[= ML2K-7WKGRL(K=+ZYX@P> 7<"?+]0RK[ON/?HXF>0P7]02P,$% @ SX,V M5Y^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)J MXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN M6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9 MWMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+ ME)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64 M,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8). MIF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^ MFO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA M6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\ M3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4 MKS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 10 M2P,$% @ SX,V5Y>*NQS $P( L !?3T\$MP>:4#M M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3 MY?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q M8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#B MG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,. M>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]0 M2P,$% @ SX,V5R0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688& MO-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S" M:+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X M=/X!4$L#!!0 ( ,^#-E=ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP M97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI* MH!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJU MDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7 MQ<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!Z MVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$ M?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( ,^#-E>X MY-H[600 !(1 8 " @0P( !X;"]W;W)K&PO7BKL

JQ"(6,P$ "(" / " 6 0 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " #/@S97)!Z;HJT #X 0 &@ M@ ' $0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #/ M@S9799!YDAD! #/ P $P @ &E$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" #O$P ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aikidopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports domh-20230921.xsd domh-20230921_lab.xml domh-20230921_pre.xml ea185678-8k_dominari.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea185678-8k_dominari.htm": { "nsprefix": "DOMH", "nsuri": "http://aikidopharma.com/20230921", "dts": { "schema": { "local": [ "domh-20230921.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "domh-20230921_lab.xml" ] }, "presentationLink": { "local": [ "domh-20230921_pre.xml" ] }, "inline": { "local": [ "ea185678-8k_dominari.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://aikidopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea185678-8k_dominari.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea185678-8k_dominari.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://aikidopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-23-078797-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-078797-xbrl.zip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end